摘要
美降之(Lovastatin)是胆固醇合成酶系中限速酶甲基羟戊二酰辅酶A(HMG·COA)还原酶的竞争性抑制剂,是目前我国用于降低血清胆固醇的有效药物之一。立平脂(Lipanthyl)也具有HMG·COA还原酶的竞争抑制作用,也是临床应用的第一线药物。我院近年来先后应用该两种药物降脂治疗,现将规察结果报道如下。
This paper reports the efficacy of Lovastatin and Lipanthyl to patients with primary hyperlipidemia in 60 cases.The results showed that,8 weeks after taking Lovastatin,the percentage of the patients whose serum Chlesterol(Ch) and Triglyceride(Tg) level dropped were 86. 87% and 53. 84% respectively. And the average dropping ratio were Ch 20. 62% .LDL-C 9. 78% .APO-B 10. 74% and Ch/HDL 29. 70% ; The average elevation ratio were HDL-C 11. 91% ,APO-A 12. 57% and APO-A/APO-B 24. 51%. There was a significent dropping of serum Tg level 8 weeks after taking Lipanthyl ,and its total efficacy was 84. 61%,however,except for Tg ,other parameters of Lipanthyl had less efficacy than Lovastatin.